Blog
RSS FeedPosted by Michael Wonder on 17 Feb 2016
Kaitaia woman's medical win
16 February 2016 - A Kaitaia woman is the first person in New Zealand to receive publicly-funded medical cannabis to control ...
Posted by Michael Wonder on 17 Feb 2016
CADTH calls for patient input on a new submission from Actelion for Uptravi
16 February 2016 - CADTH has received notice of a pending submission from Actelion for Uptravi (selexipag) for the treatment of ...
Posted by Michael Wonder on 15 Feb 2016
Alirocumab hypercholesterolemia or mixed dyslipidaemia: additional benefits not covered says IQWiG
15 February 2016 - An additional benefit compared to the appropriate comparator therapies has not been established for this substance because ...
Posted by Michael Wonder on 15 Feb 2016
PHARMAC invites proposals for the supply of various vaccines in New Zealand
15 February 2016 - PHARMAC is interested in considering any proposal from suppliers of various vaccines. ...
Posted by Michael Wonder on 12 Feb 2016
Approval of amendments to the listing of some respiratory products
12 February 2016 - PHARMAC is pleased to announce the approval of amendments to existing listing agreements with Novartis New Zealand ...
Posted by Michael Wonder on 11 Feb 2016
'I wouldn't want to be a cancer patient in England': Drug company boss slams NHS watchdog for denying patients life-changing treatments
11 February 2016 - Erik Nordkamp, managing director of Pfizer UK, said England already had one of the poorest outcomes for ...
Posted by Michael Wonder on 11 Feb 2016
Ministers scramble to introduce new NHS cancer drugs scheme
11 February 2016 - Ministers have less than two months to thrash out a new system for financing cancer drugs in ...
Posted by Michael Wonder on 11 Feb 2016
Summary of responses to PHARMAC’s consultation on improving access to medicines and devices in primary care
9 February 2016 - PHARMAC received feedback from a range of stakeholders including suppliers, wholesalers, general practice and their professional bodies ...
Posted by Michael Wonder on 11 Feb 2016
Agenda for the 17 February 2016 TC meeting
11 February 2016 - The Transparency Commission will consider the reimbursement of sonidegib diphosphate (Odomzo), emtricitabine with elvitegravir and cobicistat and ...
Posted by Michael Wonder on 10 Feb 2016
MPs find no evidence that Cancer Drugs Fund was spent wisely
5 February 2016 - A total of £1.27bn (€1.7bn; $1.9bn) has so far been spent on the Cancer Drugs Fund in ...
Posted by Michael Wonder on 10 Feb 2016
Sixty seconds on . . . the Cancer Drugs Fund
9 February 2016 - Since its creation in 2010, £1.27bn. It has treated 80 000 people, roughly, so the average has been ...
Posted by Michael Wonder on 09 Feb 2016
More treatments funded by PHARMAC for respiratory disease
9 February 2016 - PHARMAC is funding six new medicines that will improve treatment options for people with chronic obstructive pulmonary ...
Posted by Michael Wonder on 08 Feb 2016
February 2016 SMC decisions news release
8 February 2016 - SMC accepts treatments for breast cancer, myeloma and ADHD. ...
Posted by Michael Wonder on 08 Feb 2016
NICE issues draft guidance on alirocumab for lipid disorder
8 February 2016 - NICE has published draft guidance not recommending alirocumab (Praluent, Sanofi/Regeneron) as an option for people with high ...
Posted by Michael Wonder on 06 Feb 2016
CADTH calls for patient input on submissions for 2 new medicines for use by patients with HIV infection
5 February 2016 - CADTH has received notice of pending submissions from Theratechnologies for Egrifta (tesamorelin acetate) for lipodystrophy in HIV-infected ...